← Leaderboards
Scott Kopetz
University Of Tx Md Anderson Can Ctr
$13,199,822
Attributed
$22,729,653
Total exposure
18
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,717,058 · 19
By mechanism
P50$13,179,683 · 5
R01$13,166,167 · 6
K12$2,729,519 · 1
U24$1,997,839 · 1
UH3$787,854 · 1
K23$673,980 · 1
Top collaborators
- Anirban Maitra10 shared
- David S. Hong8 shared
- Stanley R Hamilton7 shared
- Rajyalakshmi Luthra5 shared
- Dipen M. Maru5 shared
- Jeffrey S. Morris5 shared
- Ryan Bruce Corcoran4 shared
- Henry Charles Manning3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- George A. Calin$5,774,539
- Eduardo Vilar Sanchez$16,310,319
- Shine Chang$18,661,173
- Anil K Sood$29,572,737
- Ronald Anthony Depinho$97,148,322
Others in their field
Top investigators on “Colorectal Cancer”
- Norman Wolmark · Nsabp Foundation, Inc.$253,344,814
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$72,920,401
- William J. Blot · Vanderbilt University$60,929,890
- Loic Le Marchand · University Of Hawaii At Manoa$57,327,999
- Ulrike Peters · Fred Hutchinson Cancer Research Center$56,201,247
- Andrew T Chan · Massachusetts General Hospital$47,099,005
Research focus
Colorectal CancerClinical TrialsResistanceTumorBaseProgramsMolecularMalignant NeoplasmsResearch PersonnelGrantBiological MarkersResponseDesignTranslatingSamplingCollaborationsColon Cancer PatientsMutationPre-ClinicalPathologyLeadChemotherapyInstitutionFunding
Grant awards (70)
Paul Calabresi Clinical Oncology Award$804,617
K12 · FY2025 · CA · contact PI
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer$711,990
R01 · FY2025 · CA
07 Gastrointestinal Cancers$24,691
P30 · FY2025 · CA · contact PI
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer$676,391
R01 · FY2024 · CA
Paul Calabresi Clinical Oncology Award$569,799
K12 · FY2024 · CA · contact PI
07 Gastrointestinal Cancers$23,220
P30 · FY2024 · CA · contact PI
MD Anderson Cancer Center SPORE in Gastrointestinal Cancer$2,203,749
P50 · FY2023 · CA · contact PI
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer$697,752
R01 · FY2023 · CA
Paul Calabresi Clinical Oncology Award$663,405
K12 · FY2023 · CA · contact PI
Administrative Core$273,686
P50 · FY2023 · CA · contact PI
Colorectal Cancer Molecular Subtype Assay Development and Validation$149,772
UH3 · FY2023 · CA
Career Enhancement Program$145,727
P50 · FY2023 · CA · contact PI
07 Gastrointestinal Cancers$18,707
P30 · FY2023 · CA · contact PI
MD Anderson Cancer Center SPORE in Gastrointestinal Cancer$2,211,341
P50 · FY2022 · CA · contact PI
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer$728,990
R01 · FY2022 · CA
Paul Calabresi Clinical Oncology Award$691,698
K12 · FY2022 · CA
MDACC-PREDICT$657,521
U24 · FY2022 · CA
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies$650,719
R01 · FY2022 · CA
Colorectal Cancer Molecular Subtype Assay Development and Validation$340,987
UH3 · FY2022 · CA
Administrative Core$268,189
P50 · FY2022 · CA · contact PI
Career Enhancement Program$152,719
P50 · FY2022 · CA · contact PI
Project 2: Building Combinatorial Therapies against KRAS-mutant Colorectal and Pancreatic Cancer$96,541
U54 · FY2022 · CA · contact PI
07 Gastrointestinal Cancers$18,707
P30 · FY2022 · CA · contact PI
MD Anderson Cancer Center SPORE in Gastrointestinal Cancer$1,987,442
P50 · FY2021 · CA · contact PI
MDACC-PREDICT$670,456
U24 · FY2021 · CA
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies$663,998
R01 · FY2021 · CA
Colorectal Cancer Molecular Subtype Assay Development and Validation$297,095
UH3 · FY2021 · CA
Administrative Core$248,431
P50 · FY2021 · CA · contact PI
Career Enhancement Program$248,430
P50 · FY2021 · CA · contact PI
Project 2: Building Combinatorial Therapies against KRAS-mutant Colorectal and Pancreatic Cancer$218,060
U54 · FY2021 · CA · contact PI
07 Gastrointestinal Cancers$18,707
P30 · FY2021 · CA · contact PI
MD Anderson Cancer Center SPORE in Gastrointestinal Cancer$2,309,154
P50 · FY2020 · CA · contact PI
MDACC-PREDICT$669,862
U24 · FY2020 · CA
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies$663,998
R01 · FY2020 · CA
Administrative Core$279,978
P50 · FY2020 · CA · contact PI
Project 2: Building Combinatorial Therapies against KRAS-mutant Colorectal and Pancreatic Cancer$222,812
U54 · FY2020 · CA · contact PI
Career Enhancement Program$151,998
P50 · FY2020 · CA · contact PI
Project 2: Building Combinatorial Therapies against KRAS-mutant Colorectal and Pancreatic Cancer$120,000
U54 · FY2020 · CA · contact PI
07 Gastrointestinal Cancers$18,675
P30 · FY2020 · CA · contact PI
MD Anderson Cancer Center SPORE in Gastrointestinal Cancer$2,275,719
P50 · FY2019 · CA · contact PI
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies$644,078
R01 · FY2019 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$612,599
R01 · FY2019 · CA · contact PI
Administrative Core$274,320
P50 · FY2019 · CA · contact PI
Colorectal Cancer Molecular Subtype Assay Development and Validation$163,706
UH2 · FY2019 · CA
Career Enhancement Program$148,800
P50 · FY2019 · CA · contact PI
07 Gastrointestinal Cancers$18,707
P30 · FY2019 · CA · contact PI
07 Gastrointestinal Cancers$5,456
P30 · FY2019 · CA · contact PI
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies$663,998
R01 · FY2018 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$616,538
R01 · FY2018 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2018 · CA
Colorectal Cancer Molecular Subtype Assay Development and Validation$214,027
UH2 · FY2018 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$623,897
R01 · FY2017 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2017 · CA
Stress Signaling Pathways and Resistance in Colorectal Cancer$332,000
R01 · FY2017 · CA · contact PI
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$659,613
R01 · FY2016 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2016 · CA
Stress Signaling Pathways and Resistance in Colorectal Cancer$316,108
R01 · FY2016 · CA · contact PI
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition$653,792
R01 · FY2015 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2015 · CA
Stress Signaling Pathways and Resistance in Colorectal Cancer$316,108
R01 · FY2015 · CA · contact PI
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer$332,000
R01 · FY2014 · CA
Stress Signaling Pathways and Resistance in Colorectal Cancer$306,625
R01 · FY2014 · CA · contact PI
Stress Signaling Pathways and Resistance in Colorectal Cancer$316,108
R01 · FY2013 · CA · contact PI
Src inhibition in Colorectal Cancer$134,796
K23 · FY2012 · CA · contact PI
Src inhibition in Colorectal Cancer$134,796
K23 · FY2011 · CA · contact PI
MicroRNAs and other non-coding RNAs in Colorectal Metastasis$315,833
R01 · FY2010 · CA
Src inhibition in Colorectal Cancer$134,796
K23 · FY2010 · CA · contact PI
MicroRNAs and other non-coding RNAs in Colorectal Metastasis$335,032
R01 · FY2009 · CA
Src inhibition in Colorectal Cancer$134,796
K23 · FY2009 · CA · contact PI
Src inhibition in Colorectal Cancer$134,796
K23 · FY2008 · CA · contact PI